Tegafur-uracil: Difference between revisions
m Protected "Tegafur-uracil": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 12: | Line 12: | ||
<references/> | <references/> | ||
[[Category:Chemotherapeutic agents]] | [[Category:Chemotherapeutic agents]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 16:42, 20 August 2012
|
WikiDoc Resources for Tegafur-uracil |
|
Articles |
|---|
|
Most recent articles on Tegafur-uracil Most cited articles on Tegafur-uracil |
|
Media |
|
Powerpoint slides on Tegafur-uracil |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Tegafur-uracil at Clinical Trials.gov Trial results on Tegafur-uracil Clinical Trials on Tegafur-uracil at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Tegafur-uracil NICE Guidance on Tegafur-uracil
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Tegafur-uracil Discussion groups on Tegafur-uracil Patient Handouts on Tegafur-uracil Directions to Hospitals Treating Tegafur-uracil Risk calculators and risk factors for Tegafur-uracil
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Tegafur-uracil |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Overview
Tegafur-uracil is a chemotherapy drug used in the treatment of cancer, primarily bowel cancer. It is also called UFT or UFUR.[1]
UFT is the first generation of DIF(DPD Inhibitory Flouropyrimidine)drug. UFT is an oral agent with combines uracil, a competitive inhibitor of DPD, with the 5-FU prodrug tegafur in a 4:1 molar ratio. Excess uracil competes with 5-FU for DPD, thus inhibiting 5-FU catabolism.